Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination.
In this study, experimental canarypox virus (ALVAC) and plasmid DNA recombinant vaccines expressing the gB, gC and gD glycoproteins of EHV-1 were assessed for their ability to protect conventional ponies against a respiratory challenge with EHV-1. In addition, potential means of enhancing serological responses in horses to ALVAC and DNA vaccination were explored. These included co-administration of the antigen with conventional adjuvants, complexation with DMRIE-DOPE and co-expression of the antigen along with equine GM-CSF. Groups of EHV primed ponies were vaccinated twice intra-muscularly with one dose of the appropriate test vaccine at an interval of 5 weeks. Two to 3 weeks after the second vaccination, ponies were infected intra-nasally with the virulent Ab4 strain of EHV-1 after which they were observed clinically and sampled for virological investigations. The results demonstrated that DNA and ALVAC vaccination markedly reduced virus excretion after challenge in terms of duration and magnitude, but failed to protect against cell-associated viremia. Noteworthy was the almost complete absence of virus excretion in the group of ponies vaccinated with ALVAC-EHV in the presence of Carbopol adjuvant or DNA plasmid formulated with aluminium phosphate. The administration of the DNA vaccine in the presence of GM-CSF and formulated in DMRIE-DOPE and of the ALVAC vaccine in the presence of Carbopol adjuvant significantly improved virus neutralising antibody responses to EHV-1. These findings indicate that DNA and ALVAC vaccination is a promising approach for the immunological control of EHV-1 infection, but that more research is needed to identify the immunodominant protective antigens of EHV-1 and their interaction with the equine immune system.
Minke
J M
JM
Merial SAS, 254 rue Marcel Mérieux, 69007 Lyon, France. jules.minke@merial.com
Fischer
L
L
Baudu
Ph
P
Guigal
P M
PM
Sindle
T
T
Mumford
J A
JA
Audonnet
J C
JC
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006566:Herpesviridae Infections / Q000276:immunology / Q000517:prevention & control / Q000662:veterinary* / Q000821:virology; D004861:Herpesvirus 1, Equid / Q000235:genetics / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006734:Horse Diseases / Q000276:immunology / Q000517:prevention & control* / Q000821:virology*; D006736:Horses; D008297:Male; D009500:Neutralization Tests / Q000662:veterinary; D016133:Polymerase Chain Reaction / Q000662:veterinary; D018709:Statistics, Nonparametric; D014611:Vaccination / Q000379:methods / Q000662:veterinary*; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use*; D014759:Viral Envelope Proteins / Q000235:genetics / Q000276:immunology; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*
C078788:ALVAC vaccine; D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D022283:Herpesvirus Vaccines; D019444:Vaccines, DNA; D014759:Viral Envelope Proteins; D014765:Viral Vaccines; C080410:glycoprotein C, Equid herpesvirus 1; C488988:glycoprotein D, Equid herpesvirus 1